Published in Oncol Rep on January 20, 2014
miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene (2015) 1.00
CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. J Clin Invest (2016) 0.92
Clinical Diagnostic Implications of Body Fluid MiRNA in Oral Squamous Cell Carcinoma: A Meta-Analysis. Medicine (Baltimore) (2015) 0.83
Identification of miR-194-5p as a potential biomarker for postmenopausal osteoporosis. PeerJ (2015) 0.81
MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo signaling and tumorigenesis in hepatocellular carcinoma. Oncol Lett (2016) 0.81
Characterization of miR-146a and miR-155 in blood, tissue and cell lines of head and neck squamous cell carcinoma patients and their impact on cell proliferation and migration. J Cancer Res Clin Oncol (2015) 0.79
miR-494 inhibits ovarian cancer cell proliferation and promotes apoptosis by targeting FGFR2. Oncol Lett (2016) 0.77
A new method for discovering disease-specific MiRNA-target regulatory networks. PLoS One (2015) 0.76
Circulating miR-223 in Oral Cancer: Its Potential as a Novel Diagnostic Biomarker and Therapeutic Target. PLoS One (2016) 0.76
Integrated microRNA-mRNA analysis revealing the potential roles of microRNAs in tongue squamous cell cancer. Mol Med Rep (2015) 0.76
miR-219-5p inhibits proliferation and clonogenicity in chordoma cells and is associated with tumor recurrence. Oncol Lett (2016) 0.75
miR-186 suppressed CYLD expression and promoted cell proliferation in human melanoma. Oncol Lett (2016) 0.75
MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol. Oncotarget (2017) 0.75
Alterations in miRNA expression patterns in whole blood of OSCC patients. In Vivo (2014) 0.76